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Abstract 
Background: The glycoprotein YKL‑40 is a new marker of early inflammation and endothelial dysfunction. Adiponec‑
tin is a collagen‑like protein with anti‑atherogenic and anti‑inflammatory effects. Increased concentrations of both 
markers have been reported in patients with type 1 diabetes (T1D).
Aim: To assess the possible role of YKL‑40 and adiponectin as a marker of subclinical cardiovascular disease in asymp‑
tomatic patients with type 1 diabetes with no history of ischemic or macrovascular heart disease and its relationship 
with other classic inflammatory biomarkers.
Methods: Concentrations of YKL‑40, adiponectin, IL‑6, IL‑1β, TNF‑ α, hsCRP and homocysteine were determined 
in 150 T1D patients (58 % men, age: 38.6 ± 8.1 years, 20.4 ± 8.1 years of evolution, BMI: 25.1 ± 3.6 kg/m2; HbA1c 
8.1 ± 2.3 %, 48 % smokers; 26 % retinopathy, microalbuminuria 9 %) and 50 controls age, sex and smoke condition 
matched. Subclinical atherosclerosis was assessed by a carotid ultrasonography and a computed tomography for 
evaluation of calcium artery calcification score (CACS).
Results: 82 % of T1D patients and 92 % of controls had a calcium score of 0. T1D patients showed a signifi‑
cantly higher mean common carotid artery intima media thickness (CIMT) compared to controls (0.55 ± 0.14 vs 
0.48 ± 0.14 mm, p = 0.01). Concentrations of YKL‑40 and adiponectin were significantly higher in T1D [42.6 (10.4–
195.0) vs ±28.7 (11.0–51.2) ng/ml, p = 0.001 and 15.8 ± 9.1 vs. 12.4 ± 5.3 mg/ml, p = 0.008], with no differences 
when compared to other inflammatory parameters. In T1D patients no association was found between YKL‑40 and 
adiponectin and screening test for subclinical arterial disease (neither CACS nor CIMT). A positive correlation was 
found between levels of YKL‑40 and age and duration of disease (r = 0.28, p = 0.003; r = 0.35, p = 0.001). There were 
no differences in the YKL‑40 in relation to the presence or absence of retinopathy or nephropathy. Levels of adiponec‑
tin were higher in patients with nephropathy (21.84 ± 8.15 vs. 14.88 ± 8.27 mg/ml, p = 0.008).
Conclusions: Type 1 diabetes patients from a Mediterranean area with a longer disease evolution, although a lower 
degree of subclinical disease, showed significatively higher concentrations of YKL‑40 and adiponectin compared with 
the controls. Therefore, we conclude that YKL‑40 and adiponectin are early inflammatory markers in diabetic subjects 
even in the presence of a low atherosclerotic background.
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Background
Type 1 diabetes mellitus (T1D) is associated with an 
increase in cardiovascular disease and higher mortality 
compared to the non-diabetic population [1, 2]. Different 
studies have demonstrated that functional and structural 
vascular changes as altered endothelial function occur at 
a very early stage of the course of T1D [3–5].
In a similar way that for type 2 diabetes (T2D), some 
authors have proposed that silent subacute inflamma-
tion is also operative in T1D as a driver of cardiovascular 
disease development. Thereby, it has been reported that 
low adiponectin levels predict cardiovascular events and 
coronary artery calcification (CAC), as well as levels of 
soluble interleukin 2 receptor correlate also with CAC 
progression [6–8].
Recently, the possible role in atherosclerosis and dia-
betes of new inflammatory markers as YKL-40 has been 
investigated. YKL-40 is a 40  kDa heparin- and chitin-
binding glycoprotein, which is expressed and secreted 
by different cell types of the immune system, differenti-
ated vascular endothelial and smooth muscle cells. This 
inflammatory glycoprotein seems to play an impor-
tant role in endothelial dysfunction and during the 
early stages of atherosclerosis [9]. Several studies have 
reported elevated YKL-40 levels in different cardiovas-
cular conditions and it has been described a positive 
association between this marker and mortality [10–17]. 
It has been reported an increased YKL-40 expression 
in patients with carotid atherosclerosis [18], as well as 
a positive correlation between common carotid artery 
intima media thickness (CIMT) and YKL-40 levels in 
patients with obstructive sleep apnea syndrome [16] and 
between arterial stiffness and YKL-40 levels in essen-
tial hypertension subjects [15]. Increased YKL-40 lev-
els have also been found both in patients with T1D and 
T2D [19–22], and particularly in T1D and T2D patients 
with microalbuminuria, suggesting that this glycoprotein 
might be used as an early marker of vascular disease [18, 
21]. A recent study has reported higher levels of YKL-40 
in asymptomatic T2D patients with suspected coronary 
artery disease (CAD) suggesting a possible association 
between this marker and CAD [23].
Adiponectin is a collagen-like protein secreted from 
the adipose tissue and it has anti-atherogenic and anti-
inflammatory effects. Hypoadiponectinemia have been 
reported associated with obesity, metabolic syndrome, 
atherosclerosis, CAD and atherogenic dyslipidemia with 
low-density lipoprotein (LDL) subfraction phenotype, as 
well as in patients with T2D [24, 25]. Nevertheless, higher 
adiponectin levels have been described in T1D patients 
and have been associated with impairment of renal func-
tion and longer evolution disease. Despite these higher 
levels and the anti-atherogenic effects of adiponectin, 
there is an increase in the cardiovascular mortality in 
T1D patients [6, 26–29].
There is scarce information concerning the possible role 
of adiponectin as an indicator of subclinical atherosclero-
sis. A recent study has shown no correlation between adi-
ponectin and CIMT in children with T1D [30].
There are no studies evaluating the association between 
YKL-40 with subclinical CAD in T1D patients. There-
fore, the aim of this study was to assess the possible role 
of YKL-40 and adiponectin as a marker of subclinical car-
diovascular disease in asymptomatic patients with T1D 
from a Mediterranean area and its potential relationship 
with other classic inflammatory biomarkers.
Methods
An initial cohort of 150 asymptomatic T1D consecutively 
followed at our outpatient clinic and a control group of 50 
subjects matched by age, sex and smoke condition were 
recruited between 2010 and 2012 in Badalona, Barcelona. 
In this cohort we evaluated the presence of subclinical 
atherosclerosis as previously reported [31]. Inclusion 
criteria were an age between 20 and 50  years and an 
evolution disease of more than 10  years. The exclusion 
criteria were a previous history of clinical macrovascu-
lar or cardiac heart disease (CHD). Current smoking and 
previously smoking condition for less than 5 years were 
included in the same category. A group of non-diabetic 
subjects matched for age, sex, body mass index (BMI) 
and smoking condition recruited from the relatives and 
staff of our hospital was also included as control group. 
All patients were under intensive insulin treatment and 
15 % of them using pump devices.
The local ethics committee, in accordance with the 
Declaration of Helsinki, approved the study; all par-
ticipants gave their written informed consent prior to 
inclusion.
Demographic and clinical data including age, sex, his-
tory of clinical macrovascular disease and microvascular 
diabetic complications, family history of early CHD in 
first degree relatives (defined as CHD occurring before 
age 55 years in men and before age 65 years in women) 
and medical treatment (antihypertensive agents, statins 
and acetylsalicylic acid) were recorded for all patients. 
BMI was calculated as weight in kilograms divided by 
height per square meter.
Diabetic nephropathy was evaluated according to uri-
nary albumin excretion. Thus, normal urinary albumin 
excretion was considered below 30 mg/24 h, microalbu-
minuria from 30 to 300  mg/24  h and proteinuria above 
300  mg/24  h. These results were confirmed on at least 
two out of three consecutive determinations. Diabetic 
retinopathy was defined by fundus oculi performed by a 
specialized ophthalmologist.
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Trained personnel collected clinical parameters (age, 
sex, height, weight, BMI, blood pressure and smoking 
habit and family history of early CHD).
Biochemical measurements
Blood samples were drawn by venipuncture at between 
8.00 and 08.30 h after an overnight fast. Plasma glucose, 
total cholesterol, high density (HDL) and low density 
(LDL) lipoprotein cholesterol, triglycerides, calcium 
(Ca) and phosphate (Ph) were measured by routine clin-
ical chemistry immediately after extraction. HbA1c was 
measured in blood samples with ethylenediaminetet-
raacetic acid (EDTA) by high-performance liquid chro-
matographic (HPLC) using a fully-automated Adams 
Menarini HI-AUTO A1c 8160 analyzer manufactured 
by Arkray (Kyoto, Japan) with an inter-assay coeffi-
cient of variation of 1.8 and 1.5 % at HbA1c levels of 4.8 
and 9.0  % respectively (reference range 4–5.8  %). This 
method is a cation exchange HPLC method certified by 
the NGSP (National Glycohemoglobin Standardization 
Program) of traceability to the Diabetes Control and 
Complications Trial Reference (DCCT) Method. Mean 
HbA1c was calculated as an average of three determi-
nations in the previous year before the inclusion in the 
study.
Serum YKL-40 was analyzed using a commercial 
ELISA assay (Quidel Speciality products, San Diego, CA 
USA), Sensitivity of the assay was 20 μg/ml. The average 
within-run and total CVs were 3.6 and 5.4 %, respectively. 
The reference interval (central 90  % interval) for chon-
drex in healthy adults was 25–95 μg/l.
Serum adiponectin concentrations were measured by a 
commercial radioimmunoassay (Linco Research, Inc., St 
Louis. MO, USA), using 125I-labeled technique. The intra- 
and inter-assay coefficients of variation (CVs) at mean 
adiponectin levels of 3, 6 and 15  μg/ml were 3.6, 6.2 
and 1.8 % intra-assay, and 9.2, 6.9 and 9.2 % inter-assay, 
respectively. Assay sensitivity was 1  μg/ml. All plasma 
samples were diluted 1:250 yielding an effective range of 
0.2–50 μg/ml.
Plasma homocysteine concentrations were measured 
using an automated enzyme chemiluminescence immu-
noassay (Immulite 2000® Siemens Healthcare Diagnos-
tics, Llanberis, UK). Assay sensitivity was 1.2 μmol/l. The 
intra- and inter-assay coefficients of variation (CVs) at 
mean homocysteine concentrations of 11 and 24.5 μmol/l 
were 8.1 and 5.6  % intra-assay, and 8.5 and 8.1  % inter-
assay, respectively (reference range 5.0–12 μmol/l).
Serum TNF- α, IL-6 and IL-1β concentrations were 
measured using an enzyme chemiluminescence immuno-
metric assay (Immulite®, Siemens Healthcare Diagnos-
tics, Llanberis, UK). For TNF-α, analytical sensitivity was 
1.7 pg/mL and interassay CV <6.8 %. For IL-6 analytical 
sensitivity was 2  pg/ml and interassay CV <7.3  %. For 
IL-1β analytical sensitivity was 1.5 pg/ml and interassay 
CV <9.1 %.
Serum high sensitivity C-reactive protein (hsCRP) 
were measured using an ultrasensitive CRP test (N High 
Sensitivity CRP) on a BN-ProSpec nephelometer (Dade 
Behring, GMBH, Marburg, Germany) with an inter-assay 
variation coefficient of 3.7 and 3.5  % for CRP concen-
trations of 2.38 and 52.2  mg/l, respectively. Assay was 
0.175 mg/l, performed using a sample dilution of 1:20.
Evaluation of subclinical atherosclerosis
A computed tomography (CT) to quantify coronary 
artery calcification score (CACS) was performed using 
a 16-slice high resolution CT ECG-gated, with retro-
spective reconstruction and with special attention to the 
coronary arteries (SOMATOM Sensation 16 and Syngo 
Calcium Scoring software for analysis and calcium cal-
cification). CACS was identified as a dense area in the 
coronary artery exceeding the threshold of 130 Houns-
field units. A total Agatston score was determined for 
each patient. The results were expressed according to the 
classification previously described by Shaw et al. [32] and 
results were transformed as a categorical variable consid-
ering positive those greater than zero and negative those 
with negative results equal to zero.
A carotid ultrasound (CU) to measure the CIMT was 
performed in all participants. Ultrasonographic images 
were acquired using high resolution B-mode ultrasound 
(Siemens Acuson Sequoia 512) with an electric linear 
array 13-5 MHz transducer. The CIMT was the result of 
the median of the tunica intima and tunica media thick-
ness in per protocol defined carotid areas (left inter-
nal carotid, right internal carotid, common carotid and 
bifurcation). Plaque number and characteristics were 
recorded.
A single trained radiologist performed evaluation and 
acquisition of CT images and CU.
Statistical methods
Continuous variables were expressed as mean standard 
deviations (SD) or median (percentile 2.5 and 97.5) and 
categorical variables as frequency and/or percentage. The 
Student’s t-test or the non-parametric Mann–Whitney U 
test, as appropriated, tested differences between groups. 
A p value less than 0.05 was considered statistically sig-
nificant. Categorical variables were compared with a χ2 
test. Correlation analyses between continuous variables 
were performed by using univariant Spearman corre-
lation analysis. All statistical analyses were performed 
using the Statistical Package for Social Science (SPSS, 
Chicago, IL, USA) for personal computers, version 12.0 
(SPSS).




Type 1 diabetes patients showed a significantly higher 
common carotid artery intima-media thickness 
(CIMT) compared to control group (0.55  ±  0.14 vs 
0.48 ± 0.14 mm, p < 0.01). There were no differences in 
the number of plaques between patients and controls. A 
low proportion of subjects in both groups presented ath-
eroma plaques (16 patients and 4 control subjects, 11 vs 
8 %), in all cases conditioning stenosis of less than 50 %.
Carotid calcification
A high proportion of subjects in both groups, patients 
and controls, displayed a CACS of 0 (92 vs 82  %), and 
only 24 T1D patients and four controls presented a cal-
cium score greater than 0. The differences between both 
groups were not significant (16.6 vs 8  % in controls, 
p = 0.236).
YKL‑40 and inflammatory markers
The baseline characteristics of the whole sample and the 
biomarkers levels are shown in Table  1. Levels of YKL-
40 were significantly higher in T1D than in controls 
[42.6 (10.4–195.0) vs ±28.7 (11.0–51.2) ng/ml p = 0.001] 
(Fig.  1) and levels of adiponectin were also significantly 
higher in T1D patients (15.8 ± 9.1 vs 12.4 ± 5.3 mg/ml, 
p = 0.008), with no differences between patients and con-
trols in the other inflammatory parameters.
YKL‑40, adiponectin and subclinical atherosclerosis imaging
When univariate correlation analyses were performed, 
we did not find association between YKL-40 and adi-
ponectin levels and any cardiovascular surrogates, nei-
ther CACS nor CIMT, either when these variables were 
evaluated as continuous or categorical variables (pres-
ence of carotid plaques and CACS 0 or ≥1). There were 
no differences between the mean YKL-40 levels of sub-
jects with a CACS of 0 and those with a CACS greater 
than 0. When T1D were categorized according to the 
presence of plaques there were no differences.
There were no positive correlations of the other inflam-
matory markers evaluated (TNF-α, IL-6, IL-1β, homo-
cysteine, hsCRP) in relation to the imaging markers of 
subclinical atherosclerosis.
YKL‑40, adiponectin, age and evolution of T1D
A positive correlation was found between levels of YKL-
40 and age and duration of disease (r = 0.28, p = 0.003; 
r  =  0.35, p  =  0.001). Levels of adiponectin were also 
positively correlated with age (r = 0.25, p = 0.01). How-
ever, no correlations were found between YKL-40 and 
adiponectin.
YKL‑40, cardiovascular risk factors and metabolic control
Patients under treatment with antihypertensive agents 
displayed significantly higher levels of YKL-40 [41.4 
(10.41–195.1) vs 28.8 (11.0–51.2) ng/ml, p = 0.04] com-
pared to those patients without treatment.
Levels of YKL-40 were not found different regarding 
gender, BMI, smoking status, treatment with statins or 
acetylsalicylic acid and HbA1c values.
YKL‑40, adiponectin and microvascular complications
There were no differences in YKL-40 concentra-
tions in relation to the presence or absence of retin-
opathy or nephropathy. Levels of adiponectin were 
higher in patients with nephropathy (21.84  ±  8.15 vs 
14.88  ±  8.27  mg/ml, p  =  0.008), but not regarding the 
presence of retinopathy; neither TNF- α, nor IL-6 and 
IL-1β showed differences regarding the presence of 
microvascular disease.
Table 1 Basal characteristics and  biomarkers levels 
of patients with type 1 diabetes and control group
Type 1 diabetes Control p
N 150 50
Age (years) 38.6 ± 8.1 38.1 ± 7.2 NS
Sex (male/female %) 58/42 56/44 NS
Evolution type  
1 diabetes (years)
20.4 ± 8.1 – –
Family history CHD (%) 20 22 NS
Body mass index  
(kg/m2)
25.1 ± 3.6 25.3 ± 4.3 NS
Systolic blood pressure 
(mmHg)
117.3 ± 13.5 – –
Diastolic blood pressure 
(mmHg)
70.9 ± 7.7 – –
Retinopathy (%) 26 – –
Nephropathy (%) 9 – –
HbA1c (%, mmol/mol) 8.1 ± 2.3 (64.9 ± 11.4) – –
Total cholesterol  
(mg/dl)
182.7 ± 25.1 191.1 ± 34.1 NS
HDL (mg/dl) 60.3 ± 15.1 61.8 ± 16.6 NS
LDL (mg/dl) 105.3 ± 21.9 111.3 ± 33.5 NS
Smoke (% yes/no) 48/52 42/58 NS
Statins (%) 21 – –
Antihypertensive (%) 15 – –
Acetylsalicylic acid (%) 16 – –
YKL‑40 (ng/ml) 42.6 (10.4–195.0) 28.7 (11.0–51.2) 0.001
Adiponectin (mg/ml) 15.4 ± 8.4 11.9 ± 5.1 0.007
TNF‑α (pg/ml) 7.5 ± 2.4 7.8 ± 1.8 NS
IL‑1β (pg/ml) 1.0 ± 1.1 1.1 ± 0.8 NS
IL‑6 (pg/ml) 2.0 ± 9.5 3.0 ± 4.0 NS
Homocysteine (mmol/l) 9.74 ± 5.1 10.9 ± 3.4 NS
hsCRP (mg/l) 2.21 ± 3,9 2.5 ± 3.9 NS
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A positive correlation was found between the con-
centrations of YKL-40 and TNF-α (r =  0.24, p =  0.02), 
but not with the other inflammatory markers evalu-
ated. IL-1β and IL-6 and TNF-α correlated among them 
(r = 0.39, p = 0.001; r = 0.36, p = 0.001, respectively).
Discussion
In this cohort of patients leaving in a Mediterranean area 
and with a relatively long disease evolution we did not find 
an association between YKL-40 and adiponectin levels 
and the presence of subclinical CAD evaluated by CACS 
and CIMT. However, our T1D patients displayed higher 
levels of YKL-40 than control subjects. These findings are 
in concordance with two previous studies performed in 
T1D [19, 20]. Rathcke et al. [20] reported elevated YKL-
40 levels in a cohort of Danish, middle-aged (50 years old) 
T1D patients, with a long diabetes duration (30  years) 
and with a high prevalence of microvascular complica-
tions (more than 50 %). Sakamoto et al. [19] showed also 
elevated levels of YKL-40 in a cohort of Japanese T1D 
patients younger than the cohort of Danish patients 
(mean age of 25  years), with less mean duration of dia-
betes (13  years) and with a lower prevalence of micro-
vascular complications (9  % of microalbuminuria, 33  % 
of retinopathy). Our cohort of T1D showed a mean age 
and duration of the disease intermediate between these 
two specific studies, but with a much lower prevalence 
of microangiopathy than the Danish cohort and similar 
to the Japanese patients. Despite that these two studies 
have described elevated concentrations of YKL-40 in T1D 
patients with microalbuminuria, it was not the case in our 
patients, indicating that YKL-40 is already increased even 
at a stage when subclinical micro and macro vascular dis-
ease is not detected with current clinical procedures or 
if it is modestly present. The low proportion of our T1D 
patients presenting nephropathy (9 %) but showing high 
YKL-40 compared to controls clearly indicates that at this 
stage of T1D evolution, inflammatory status is already 
activated. Moreover, we did not find higher levels of YKL-
40 in nephropathy patients at the stage of positive micro-
albuminuria, and although we did not find differences 
according to the presence or absence of retinopathy, prob-
ably due to the low number of subjects included in our 
cohort, all the data taken together suggest that more pro-
spective studies are probably needed in order to clarify if 
relevant changes in the magnitude of YKL concentration 
are detected over time and in relation to the appearance 
of microvascular disease.
Several clinical studies documented elevated YKL-40 
levels in patients with cardiovascular disease, including 
CAD, peripheral artery disease and stroke, either with or 
the coexistence of diabetes. An association has also been 
described between higher YKL-40 levels and an increased 
mortality, especially in elderly persons with stable CAD 
[11–14]. Nevertheless, there are no studies yet aimed 
to determine the possible role of this glycoprotein in 
patients with T1D and cardiovascular disease. The preva-
lence of subclinical CAD was low in our cohort of asymp-
tomatic T1D patients and we did not find association 
between YKL-40 levels and any cardiovascular surrogate, 
neither CACS nor CIMT, either when these variables 
were evaluated as continuous or categorical variables, 
thus suggesting that YKL-40 elevation is more a marker 
of increased inflammation in T1D patients, rather than 
one indicating subclinical disease. In our cohort, there 
was a minimal degree of overlap between control and 
patients, which seems to reflect that with a so low degree 
of subclinical disease in our diabetic cohort, inflamma-
tion is a state substantially linked to T1D before organ 
lesions are detectable, and which concentrations start 
to increase probably early after diagnosis. This finding is 
in accordance with the Japanese cohort, in which there 
was no significant correlation between YKL-40 levels and 
CIMT [19]. The only relationship we found was that in 
patients treated with antihypertensive drugs, YKL-40 was 
higher, although in those with established nephropathy 
there were no differences; we cannot at this point spec-
ulate whether these differences are due to the fact that 
those patients had a higher degree of vascular lesion or to 
the antihypertensive treatment itself. At the low level of 
subclinical CAD of our population when compared to the 
controls, there were no differences in the rest of circulat-
ing concentrations of classical inflammatory biomarkers 
studied between the two groups. Although we did not 
find correlation in this cross-sectional evaluation of YKL-
40 with metabolic control—measured as A1c levels—it 
will be interesting to study if YKL-40 concentrations are 
Fig. 1 Comparison of serum YKL‑40 levels between patients with 
type 1 diabetes patients and control group. Data are median levels 
(range)
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modified by intensification of metabolic parameters or in 
a broader range of A1c.
Our lack of correlation between adiponectin and 
CIMT is in concordance with a previous study conducted 
in children with T1D [30]. A positive correlation between 
higher concentrations of adiponectin and the presence of 
microalbuminuria was also found in this group of T1D 
patients. Also, this positive correlation has been reported 
by other authors [28, 29].
Conclusions
In T1D patients from a Mediterranean area with a long 
disease evolution although a low degree of subclinical 
disease, we found significatively higher concentrations 
of YKL-40 and adiponectin compared with the controls. 
Therefore, we conclude that YKL-40 and adiponectin are 
early inflammatory markers in diabetic subjects with low 
atherosclerotic background. Further studies with a large 
number of patients will be necessary in order to evalu-
ate the usefulness of changes in YKL-40 and adiponectin 
concentrations in progressive atherosclerotic diabetic 
disease, as well as its potential role as predictor bio-
marker of vascular disease in T1D.
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